Re­searchers seek FDA trans­paren­cy on use of sur­ro­gate end­points out­side of on­col­o­gy

In a study pub­lished Mon­day in JA­MA, re­searchers are call­ing on the FDA to share more about how the agency con­sid­ers the use of sur­ro­gate mark­ers as pri­ma­ry end­points out­side of on­col­o­gy tri­als.

Sur­ro­gate end­points are used fre­quent­ly in can­cer tri­als for ac­cel­er­at­ed ap­provals. In oth­er dis­eases, the FDA has been more will­ing to ac­cept the un­cer­tain­ty from a sur­ro­gate mark­er, so long as a po­ten­tial drug could meet an un­met need and there are con­fir­ma­to­ry stud­ies on­go­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER